journal
Journals Alimentary Pharmacology & Ther...

Alimentary Pharmacology & Therapeutics

https://read.qxmd.com/read/38779929/letter-early-real-world-evidence-from-the-united-arab-emirates-of-the-persistence-effectiveness-and-safety-of-risankizumab-for-the-treatment-of-crohn-s-disease
#41
LETTER
Maryam Alahmad, Mohammed Nabil Quraishi, Shaima Wasim Khan, Nadeen Mamon Omar, Talha A Malik
No abstract text is available yet for this article.
May 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38779926/letter-early-real-world-evidence-from-the-united-arab-emirates-of-the-persistence-effectiveness-and-safety-of-risankizumab-for-the-treatment-of-crohn-s-disease-authors-reply
#42
LETTER
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W Leong
No abstract text is available yet for this article.
May 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38778481/liver-function-and-portal-systemic-shunting-quantified-by-the-oral-cholate-challenge-test-and-risk-for-large-oesophageal-varices
#43
JOURNAL ARTICLE
Tarek Hassanein, Andrew P Keaveny, Parvez Mantry, Alastair D Smith, Michael P McRae, John Kittelson, Steve Helmke, Gregory T Everson
BACKGROUND: The quantitative HepQuant SHUNT test of liver function and physiology generates a disease severity index (DSI) that correlates with risk for clinical complications, such as large oesophageal varices (LEVs). A derivative test, HepQuant DuO, generates an equivalent DSI and simplifies testing by requiring only oral administration of the test solution and two blood samples at 20 and 60 min. AIMS: Since the DSIs measured from DuO and SHUNT are equivalent, we compared the diagnostic performance for large oesophageal varices (LEVs) between the DSIs measured from DuO and SHUNT tests...
May 22, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38773791/editorial-infliximab-induction-therapy-in-paediatric-crohn-s-disease-a-cost-effective-strategy-authors-reply
#44
EDITORIAL
Stephanie A Vuijk, Lissy de Ridder
No abstract text is available yet for this article.
May 21, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38773786/editorial-infliximab-induction-therapy-in-pediatric-crohn-s-disease-a-cost-effective-strategy
#45
EDITORIAL
Neil Chanchlani, Richard K Russell
No abstract text is available yet for this article.
May 21, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38773759/editorial-unravelling-real-world-impact-of-second-line-therapies-in-primary-biliary-cholangitis-time-to-change-our-targets
#46
EDITORIAL
Guilherme Grossi Lopes Cançado
No abstract text is available yet for this article.
May 21, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38773748/editorial-unravelling-real-world-impact-of-second-line-therapies-in-primary-biliary-cholangitis-time-to-change-our-targets-authors-reply
#47
EDITORIAL
C M Fernández-Rodríguez, M L Gutierrez, A Olveira
No abstract text is available yet for this article.
May 21, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38768298/randomised-clinical-trial-design-of-the-synergy-nash-phase-2b-trial-to-evaluate-tirzepatide-as-a-treatment-for-metabolic-dysfunction-associated-steatohepatitis-and-modification-of-screening-strategy-to-reduce-screen-failures
#48
JOURNAL ARTICLE
Raj Vuppalanchi, Rohit Loomba, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins, Bram Brouwers, Mark L Hartman
BACKGROUND: The use of histological inclusion criteria for clinical trials of at-risk metabolic dysfunction-associated steatohepatitis (MASH) is often associated with high screen failure rates. AIMS: To describe the design of a trial investigating tirzepatide treatment of MASH and to examine the effect of new inclusion criteria incorporating the use of the FibroScan-AST (FAST) score on the proportion of patients meeting histological criteria. METHODS: SYNERGY-NASH is a Phase 2b, multicentre, randomised, double-blinded, placebo-controlled trial in patients with biopsy-confirmed MASH, F2-F3 fibrosis and NAFLD Activity Score ≥4...
May 20, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38760924/editorial-another-brick-in-the-cdst-wall-authors-reply
#49
EDITORIAL
Kyuwon Kim, Byong Duk Ye
No abstract text is available yet for this article.
May 17, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38760922/editorial-another-brick-in-the-cdst-wall
#50
EDITORIAL
Aurelien Amiot, Meyer Antoine, Franck Carbonnel
No abstract text is available yet for this article.
May 17, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38757852/editorial-has-metald-met-the-presumption
#51
EDITORIAL
Chee-Kiat Tan
No abstract text is available yet for this article.
May 17, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38757828/editorial-has-metald-met-the-presumption-authors-reply
#52
EDITORIAL
Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Loomba, Masayuki Kurosaki
No abstract text is available yet for this article.
May 17, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38757447/editorial-making-lower-gi-endoscopy-referrals-more-fit-for-purpose
#53
EDITORIAL
Neasa Mc Gettigan, Roland Valori
No abstract text is available yet for this article.
May 16, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38757310/ap-t-editors-declarations-of-interest
#54
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
May 16, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38745540/meta-analysis-intestinal-ultrasound-to-evaluate-colonic-contents-and-constipation
#55
REVIEW
R M Mathias, M K W Chu, S Edwards, A S Day, C Ma, V Jairath, R V Bryant
BACKGROUND: Constipation can be diagnosed clinically using the Rome criteria. Ultrasound (US), which lacks the radiation exposure of conventional X-ray, holds promise as a non-invasive tool to evaluate colonic contents and constipation. AIM: To examine the role of US in the assessment of constipation. METHODS: We performed a systematic search of Embase (OVID, 1984), Medline (Ovid, 1946), Cochrane Central, ClinicalTrials.gov and Australia New Zealand Clinical Trials Registry from database inception to 26 January 2024 according to PRISMA guidelines and prospectively registered with PROSPERO...
May 15, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38742605/enteral-nutrition-compared-with-corticosteroids-in-children-with-crohn-s-disease-a-long-term-nationwide-study-from-the-epi-iirn
#56
JOURNAL ARTICLE
Luba Plotkin, Rachel Buchuk, Rona Lujan, Gili Focht, Shira Greenfeld, Revital Kariv, Yiska Loewenberg Weisband, Natan Lederman, Eran Matz, Iris Dotan, Ram Reifen, Dan Turner
BACKGROUND: Both corticosteroids and exclusive enteral nutrition (EEN) have been used as induction therapy in children with Crohn's disease (CD). AIM: To compare in a nationwide study the long-term outcomes of children with CD receiving either EEN or corticosteroids as induction therapy. METHODS: We retrieved data of all children diagnosed with CD (2005-2020) from the epi-IIRN cohort covering 98% of the Israeli population. The primary outcome was time to complicated disease course (i...
May 14, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38726864/letter-intestinal-permeability-accounting-for-ongoing-gastrointestinal-symptoms-following-endoscopic-remission-in-ibd-authors-reply
#57
LETTER
Arta Aliu, Daan H C A Bosch, Daniel Keszthelyi, Ashkan Rezazadeh Ardabili, Jean-Frederic Colombel, Rachel Sawyer, Hans Törnblom, Ailsa Hart, Daisy M A E Jonkers, Marieke J Pierik, Zlatan Mujagic
No abstract text is available yet for this article.
May 10, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38726810/letter-intestinal-permeability-accounting-for-ongoing-gastrointestinal-symptoms-following-endoscopic-remission-in%C3%A2-ibd
#58
LETTER
Rupert W Leong, Vipul Jairath, Christopher Ma
No abstract text is available yet for this article.
May 10, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38716823/outcomes-of-patients-with-hepatocellular-carcinoma-treated-with-atezolizumab-plus-bevacizumab-in-real-world-clinical-practice-who-met-or-did-not-meet-the-inclusion-criteria-for-the-phase-3-imbrave150-trial
#59
JOURNAL ARTICLE
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomomitsu Matono, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Yohei Koizumi, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo
BACKGROUND: Atezolizumab plus bevacizumab (Atezo/Bev) is frequently selected as the primary systemic therapy for hepatocellular carcinoma (HCC). AIMS: To investigate the outcomes of patients with HCC treated with Atezo/Bev in a real-world setting based on whether they met the inclusion criteria for the phase 3 IMbrave150 trial. METHODS: A total of 936 patients were enrolled. There were 404 patients who met the inclusion criteria of the phase 3 IMbrave150 trial (IMbrave150 group) and 532 who did not (non-IMbrave150 group)...
May 8, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38715276/letter-potential-confounders-might-exaggerate-the-risk-of-rheumatoid-arthritis-in-patients-with-microscopic-colitis
#60
LETTER
Fang Yan, Pengshuang Shi, Shimin Wu, Jie Yang, Dejun Cui
No abstract text is available yet for this article.
May 7, 2024: Alimentary Pharmacology & Therapeutics
journal
journal
29552
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.